methyl N-[(2S,3R)-1-[(2S)-2-[6-[(2R,5R)-1-[3,5-difluoro-4-[4-(4-fluorophenyl)piperidin-1-yl]phenyl]-5-[6-fluoro-2-[1-[(2S,3R)-3-methoxy-2-(methoxycarbonylamino)butanoyl]pyrrolidin-2-yl]-3H-benzimidazol-5-yl]pyrrolidin-2-yl]-5-fluoro-1H-benzimidazol-2-yl]pyrrolidin-1-yl]-3-methoxy-1-oxobutan-2-yl]carbamate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: methyl N-[(2S,3R)-1-[(2S)-2-[6-[(2R,5R)-1-[3,5-difluoro-4-[4-(4-fluorophenyl)piperidin-1-yl]phenyl]-5-[6-fluoro-2-[1-[(2S,3R)-3-methoxy-2-(methoxycarbonylamino)butanoyl]pyrrolidin-2-yl]-3H-benzimidazol-5-yl]pyrrolidin-2-yl]-5-fluoro-1H-benzimidazol-2-yl]pyrrolidin-1-yl]-3-methoxy-1-oxobutan-2-yl]carbamate
• 化学式: C₅₇H₆₅F₅N₁₀O₈
• 分子量: 1113.2
• InChiKey: VJYSBPDEJWLKKJ-OGXSJQIDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.4
• 重原子数：
  80
• 可旋转键数：
  17
• 环数：
  10.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  200
• 氢给体数：
  4
• 氢受体数：
  17

文献信息

• US20140275099A1
  申请人：——

  公开号：US20140275099A1

  公开（公告）日：2014-09-18
• Solid Pharmaceutical Compositions for Treating HCV
  申请人：AbbVie Inc.

  公开号：US20210023012A1

  公开（公告）日：2021-01-28

  The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first type of film-coated granules which comprise 50 mg of Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second type of film-coated granules which comprise 20 mg of Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.